$ILMN

Meister Keith A. sold $11.4M of ILMN (indirect holdings)

Meister Keith A. sold 70,262 indirectly-held shares of ILLUMINA, INC. (ILMN) at $162.41 ($11.41M total) on 2026-06-01.

Original reporting
SEC EDGAR · Meister Keith A.
Published Jun 1, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
medium confidence
Mentioned
$ILMN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

This disclosure updates the market on insider selling activity but does not provide new operational or financial information about Illumina.

02

Market read

Traders may monitor for follow-on insider activity, but the article alone is unlikely to drive a major repricing.

03

What to watch

The filing notes indirect ownership and no 10b5-1 plan; without context on tax/liquidity needs or prior sale patterns, interpreting intent is uncertain.

Relevance 6/10Novelty 3/10Timing: Filed today (2026-06-01) — potential intraday sentiment read-through from insider selling.

Background

SEC Form 4 reports insider transactions by directors/officers/10% owners; these are often used as sentiment/positioning signals rather than fundamental catalysts.

Company-level read

Ticker impact

$ILMNNeutralMedium confidence
Context

Illumina director Keith A. Meister sold 70,262 shares in an open-market transaction totaling about $11.41M, disclosed via SEC Form 4.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any impact is likely short-lived unless follow-on selling appears.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/guidance/M&A). It provides a datapoint on selling activity, but the article does not indicate a change in company outlook or a forced sale.

Market effects

Limited read-through to biotech/genomics tools sentiment; no sector-wide catalyst is described.

None indicated; US-listed single-name Form 4 disclosure.

None indicated; transaction is company-specific and not tied to global events.

Counterpoint

A director open-market sale may be routine diversification/plan-related and not a signal of deteriorating fundamentals, especially without a 10b5-1 plan detail.

Key entities

  • Illumina, Inc.

    US-listed genomics company subject of the insider transaction disclosure.

  • Keith A. Meister

    Director who sold 70,262 shares for ~$11.41M on 2026-06-01.

Related articles

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

$ILMNMedAI 8/10

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

$ILMNHigh

ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.